Cash Flow Statement (Annual)

SEP / Spectra Energy Partners LP Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Profit Loss - - 585,000 595,000 1,086,000 1,027,000 1,265,000 1,239,000 703,000
  Depreciation Amortization And Accretion Net - - - - - - - - -
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Deferred Income Tax Expense Benefit 1,200 -1,000 1,100 1,400 -354,000 27,000 3,000 4,000 3,000
    Income Loss From Equity Method Investments 70,700 75,100 107,300 107,600 89,000 133,000 167,000 127,000 307,000
    Equity Method Investment Dividends Or Distributions 74,300 81,100 116,300 111,600 97,000 131,000 160,000 110,000 152,000
    Increase Decrease In Regulatory Liabilities - - - - - - 0 0 860,000
    Increase Decrease In Other Operating Capital Net - - - - - - 43,000 84,000 139,000
  Net Cash Provided By Used In Operating Activities 159,700 184,800 220,100 240,800 1,029,000 1,333,000 1,522,000 1,462,000 1,610,000
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment 20,300 25,800 98,400 42,300 1,019,000 1,081,000 1,883,000 2,334,000 1,888,000
  Payments To Acquire Interest In Subsidiaries And Affiliates - - - 513,000 280,000 160,000 124,000 251,000 337,000
  Payments To Acquire Intangible Assets - - - - - 0 0 80,000 40,000
  Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital - - - 16,000 83,000 163,000 450,000 50,000 33,000
  Payments Of Distributions To Affiliates - - - - 0 0 248,000 148,000 0
  Payments To Acquire Held To Maturity Securities - - 0 0 51,000 43,000 44,000 39,000 20,000
  Proceeds From Sale And Maturity Of Held To Maturity Securities - - - - - - - - -
  Payments To Acquire Available For Sale Securities - 239,000 891,600 630,100 5,865,000 0 95,000 714,000 69,000
  Proceeds From Sale And Maturity Of Available For Sale Securities 31,600 30,000 1,091,100 489,400 6,006,000 0 84,000 715,000 76,000
  Increase Decrease In Restricted Cash - - - - - 0 14,000 -9,000 -1,000
  Cash Divested From Deconsolidation - - - - - - 0 0 67,000
  Payments For Proceeds From Other Investing Activities - - -10,600 -300 -6,000 -1,000 0 1,000 -2,000
  Net Cash Provided By Used In Investing Activities -249,400 -507,800 -286,000 -501,000 -3,689,000 -1,077,000 -1,830,000 -2,754,000 -2,289,000
Net Cash Provided By Used In Financing Activities
  Proceeds From Issuance Of Long Term Debt - 207,200 499,400 200,000 2,287,000 0 994,000 800,000 670,000
  Repayments Of Long Term Debt - - 207,200 150,000 46,000 441,000 32,000 280,000 822,000
  Proceeds From Repayments Of Commercial Paper - - - 309,000 2,000 569,000 -431,000 98,000 1,408,000
  Payments Of Dividends Minority Interest - - 18,000 18,000 19,000 29,000 31,000 30,000 49,000
  Proceeds From Minority Shareholders - - 0 0 23,000 145,000 248,000 743,000 418,000
  Proceeds From Issuance Of Common Limited Partners Units 212,200 220,800 217,900 148,200 217,000 334,000 558,000 1,080,000 174,000
  Payments Of Capital Distribution 118,400 145,900 189,300 213,900 266,000 815,000 961,000 1,061,000 1,227,000
  Proceeds From Payments For Other Financing Activities -300 -1,600 -6,400 -200 -5,000 0 -9,000 -10,000 -2,000
  Net Cash Provided By Used In Financing Activities 71,000 338,200 39,300 280,000 2,733,000 -237,000 336,000 1,340,000 570,000
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - - - - - -
Supplemental Cash Flow Information
  Capital Expenditures Incurred But Not Yet Paid 700 800 2,800 300 74,000 94,000 140,000 247,000 54,000
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - -

Peers - Natural Gas Transmission (4922)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 84756N109